Skip to search formSkip to main contentSkip to account menu

IMMU-132

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

sacituzumab govitecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract OT2-07-05: A phase III, randomized trial of sacituzumab govitecan (IMMU-132) vs treatment of physician choice (TPC) for metastatic triple-negative breast cancer (mTNBC)
Background: Metastatic TNBC has an aggressive course with limited therapy options and poor survival. Sacituzumab govitecan (IMMU… 
2017
2017
Abstract P4-22-15: Sacituzumab govitecan (IMMU-132), an anti-Trop-2-SN-38 antibody-drug conjugate (ADC) for the treatment of relapsed/refractory, metastatic triple-negative breast cancer (mTNBC…
Background . mTNBC has an aggressive course with limited effective therapy options and a median progression-free survival (PFS… 
2016
2016
Abstract P6-15-02: Synthetic lethality in TNBC mediated by an anti-Trop-2 antibody-drug conjugate, sacituzumab govitecan (IMMU-132), when combined with paclitaxel or the PARP inhibitor, olaparib
Background: In current clinical trials (ClinicalTrials.gov, NCT01631552), triple-negative breast cancer (TNBC) patients treated… 
2016
2016
PRECLINICAL STUDY ON ENHANCING SACITUZUMAB GOVITECAN ( IMMU-132 ) ACTIVITY IN SN-38-RESISTANT CANCER CELLS
  • 2016
  • Corpus ID: 32683647
Morris Plains, NJ, August 18, 2016 --Immunomedics, Inc. (Nasdaq: IMMU) today announced that adding an inhibitor of ATP-binding… 
2015
2015
IMMU-132 Encouraging in Previously Treated Metastatic Lung Cancer
The investigational agent IMMU-32 is well-tolerated in patients with previously-treated metastatic lung cancer, and interim…